Universitätsklinikums
Freiburg — Research and clinical group at the University of Freiburg,
Germany, with special expertise in familial pheochromocytoma/paraganglioma and
hypertension. A special outpatient clinic with associated research office offers
personal interviews and consultation for patients and a a research laboratory
for molecular genetic analyses. Patients, their family members and colleagues
are welcome to contact us any time. University
of California, San Francisco, CA, USA — High dose 131I-MIBG (metaiodobenzylguanadine)
is currently being used to treat patients with malignant pheochromocytomas and
paragangliomas. This therapy is available at the University of California, San
Francisco (UCSF) under a Phase II protocol that has been approved by three UCSF
review boards: The Committee on Human Research, The Comprehensive Cancer Center
Protocol Committee, and the Pediatric Clinical Research Center. [details] National
Institute of Health, Bethesda, MD, USA — The NIH is a major referral
center for patients with suspected or proven pheochromocytoma or with a genetic
predisposition to develop the tumor. Because the primary mission
of the NIH is to conduct and support medical research, all
NIH Clinical Center patients are enrolled into research studies that have
undergone rigorous review and approval processes by Institution Review Boards
(IRB's). This ensures that the study meets the appropriate standards
for clinical research within the NIH intramural program. [details] Royal
North Shore Hospital, Sydney, Australia — During the past three years,
mutations have been identified in SDHB and SDHD (genes encoding for SDHB and SDHD,
component peptides of mitochondrial complex II) in patients with familial pheochromocytoma
and apparently sporadic pheochromocytoma. We have established an International
SDH Consortium and are seeking international cooperation and treatment and study
of patients with these diseases. [details] If
you have a link that you would like added to this page, please contact our webmaster
at webmaster@pressor.org | 
